Abstract
Background
Puerto Rico has experienced the full impact of the COVID-19 pandemic. Since SARS-CoV-2, the virus that causes COVID-19, was first detected on the island in March of 2020, it spread rapidly though the island’s population and became a critical threat to public health.
Methods
We conducted a genomic surveillance study through a partnership with health agencies and academic institutions to understand the emergence and molecular epidemiology of the virus on the island. We sampled COVID-19 cases monthly over 19 months and sequenced a total of 753 SARS-CoV-2 genomes between March 2020 and September 2021 to reconstruct the local epidemic in a regional context using phylogenetic inference.
Results
Our analyses reveal that multiple importation events propelled the emergence and spread of the virus throughout the study period, including the introduction and spread of most SARS-CoV-2 variants detected world-wide. Lineage turnover cycles through various phases of the local epidemic were observed, where the predominant lineage was replaced by the next competing lineage or variant after ~4 months of circulation locally. We also identified the emergence of lineage B.1.588, an autochthonous lineage that predominated in Puerto Rico from September to December 2020 and subsequently spread to the United States.
Conclusions
The results of this collaborative approach highlight the importance of timely collection and analysis of SARS-CoV-2 genomic surveillance data to inform public health responses.
Plain language summary
The COVID-19 pandemic reached Puerto Rico in March 2020. To understand the impact of SARS-CoV-2 on Puerto Rico, we formed a partnership with universities and local government to study the genetic sequence of viruses sampled from infected people between March 2020 and September 2021. Our results show that the local epidemic was initiated and sustained by frequent importation of a wide diversity of SARS-CoV-2 lineages and variants, some of which circulated for some time in the island. We also detected a lineage of SARS-CoV-2, named B.1.588, that was first detected in Puerto Rico and subsequently spread to the United States. This study highlights the importance of the study of viral genetic data to inform public health responses.
Similar content being viewed by others
Introduction
The current coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was initially declared a Public Health Emergency of International Concern in January 20201,2. Despite global efforts to interrupt transmission chains with quarantine, isolation, and travel restrictions at the onset of the pandemic, SARS-CoV-2 spread rapidly across the globe, creating a global pandemic and threat to human health worldwide. By November 15th, 2021, the World Health Organization (WHO) reported 253 million confirmed COVID-19 cases in 222 countries and over 5 million deaths3,4. SARS-CoV-2 reached all 50 states of the United States and associated territories, including Puerto Rico, by March 2020, after multiple introductions by travelers with infection5,6,7. The rapid spread across the United States was primarily propelled by interstate transmission chains and air travel to the associated territories6,8,9.
SARS-CoV-2 is an enveloped virus with a single-stranded positive-sense RNA genome of ~30,000 base pairs. During replication, a virus-encoded exonuclease provides a proof-reading activity that contributes to the observed low mutation rate and stable genome10,11. Nevertheless, the unprecedented spread of SARS-CoV-2 globally and the wealth of genomic sequence data available through the international initiative for genomic studies and surveillance has facilitated phylodynamic approaches to infer viral evolutionary rate, growth rate, and the estimated time of origin for specific outbreaks11. Studies have revealed that the viral genome has been accumulating mutations of concern, especially in the spike protein region, which confer phenotypes with increased fitness and pathogenicity12,13,14. Increased infectivity, resistance to monoclonal antibody therapy and evasion of the immune response were among the most frequently observed phenotypes attributed to WHO-monitored variants; these phenotypes often dominated transmission and replacement of other lineages upon emergence15,16,17,18. The Variant Being Monitored (VBM) B.1.1.7 (Alpha) was first identified in the United States in late December 2020 and was then characterized by a considerable increase in COVID-19 incidence associated with increased infectivity and occasionally more severe disease manifestations that increased hospitalization rates19,20. Alpha became the dominant variant, especially in Europe and the United States, until the emergence of Variant of Concern (VOC) B.1.617.2/AY.x (Delta), first identified in the United States in May 2021, which developed into a prominent variant with an apparent higher virulence and pathogenic phenotype21,22,23. Because of the potential for increased transmissibility, morbidity mortality, and decreased efficacy of vaccines and other intervention strategies, monitoring the spread of variants (VBMs and VOCs) rapidly became a public health concern and priority24,25.
Puerto Rico, an unincorporated territory of the United States, is a densely populated island and a popular tourist destination located in the Caribbean basin. SARS-CoV-2 was first identified in Puerto Rico on March 13th, 2020, in two European travelers who arrived on a cruise ship and in one local resident who had close contact with family members with recent travel history. Additional travel-related and local cases were confirmed within the following weeks26. In response to the emerging threat, the government of Puerto Rico executed the most restrictive (compared to the United States) national stay-at-home order on March 15th, 2020, to mitigate transmission while preparing the public health infrastructure for the imminent impact27,28. Travel restrictions imposed by the United States during the initial pandemic minimized international traffic to Puerto Rico, although domestic travel from the United States continued. Puerto Rico represents a unique epidemiologic setting in a geographically isolated location (an island), but with a regular influx of travelers mostly from the United States. This is an ideal setting to monitor introduction and spread of SARS-CoV-2 variants and answer questions to help inform SARS-CoV-2 spread and disease prevention strategies. Puerto Rico’s public health response incorporated extensive molecular surveillance to the increased laboratory capacity, which presented a unique opportunity to study the impact of SARS-CoV-2 variant turnover, local dissemination, and evolution during a period of changing epidemiology and public health responses.
In response to the impending local epidemic, we established a partnership with the local health authorities and academia to conduct a genomic surveillance initiative to sample complete genomes of SARS-CoV-2 across the island through time, monitor lineage circulation, and understand the genomic epidemiology of the COVID-19 pandemic in Puerto Rico. This report presents the results from 19 months of genomic surveillance and phylogenetic analyses, which identified multiple introduction events that propelled the rapid expansion and persistent transmission of the virus on the island and lead to the establishment of an autochthonous lineage between August 2020 and January 2021.
Methods
Epidemiological data
We retrieved the number COVID-19 cases reported by the Puerto Rico Department of Health (PRDH) from March 2020 to 30 September 2021 from the PRDH database dashboard on 1 December 2021 available here https://covid19datos.salud.gov.pr/. The collection of cases includes cases classified as confirmed (by molecular tests) or probable (by antigen tests) and plotted by date of sample collection.
Patient sample selection
Nasopharyngeal swab samples pre-selected for genomic surveillance were received from COVID-19 passive surveillance conducted by PRDH, the Ponce Health Sciences University (PHSU), and hospital-based acute febrile illness surveillance conducted by the Centers for Disease Control and Prevention (CDC) Dengue Branch. A total of 785 samples were collected from March 2020 to September 30th, 2020, from the seven health regions of the island, including 63 out of the 78 municipalities, and selection criteria included all samples with SARS-CoV-2 detected by reverse-transcriptase polymerase chain reaction (RT-PCR), viral load (CT < 28) and sufficient residual sample volume stored at −80 °C 29. All samples were de-linked from patient identifiable information and processed under the guidelines approved by the CDC and Ponce School of Medicine institutional review boards (IRB) protocol 6731, which waived the need for informed consent for sequencing of residual samples.
Lineage frequency analysis
The frequency of SARS-CoV-2 lineage detection in Puerto Rico was calculated using the total number of SARS-CoV-2 genomes published in the Global Initiative on Sharing All Influenza Data (GISAID) (https://www.gisaid.org) with collection dates ranging between March 1st, 2020 and September 30th, 2021. All complete genome sequences and metadata were retrieved from the GISAID database as of October 31st, 2021. The dataset was filtered for complete genome data, high-coverage data, and complete collection date for a final dataset of 2514 entries. Lineage assignment on GISAID was determined by the Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin)30,31. R with ggplot package was used to calculate lineage frequency and plot the graph focusing on the following lineages of interest: B.1.1.7 (Alpha), P.1 + P.1.1 (Gamma), B.1.588, Delta (B.1.617.2+AY.x), B.1.427 + B.1.429 (Epsilon), B.1.526 (Iota), B.1.621/1 (Mu), and all other Pangolin-designated B lineages grouped as Other. No genomes collected in May 2020 have been published in GISAID by October 31st, 2021.
Complete genome sequencing and assembly
Complete SARS-CoV-2 genome sequences were generated directly from clinical nasopharyngeal samples. Viral RNA was extracted from viral transport media using the automated MagNA Pure 96 system (Roche) with the MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume Kit (Roche) following manufacturer-recommended protocols for 0.2 mL sample input volume and 0.1 mL RNA elution volume. MP96 external lysis buffer was used to pre-treat the samples for neutralization and assist the lysis process. First strand cDNA was synthesized with random hexamers using SuperScript IV reverse transcriptase (ThermoFisher), and tiling PCR amplicons were generated using Q5® high-fidelity DNA polymerase (New England Biolabs) and the ARTIC nCoV-2019 V3 primer scheme purchased from Integrated DNA Technologies (https://github.com/artic-network/artic-ncov2019/blob/master/primer_scheme/nCoV-2019/V3/nCov-2019.tsv). Candidate samples for sequencing presented clearly visible bands of target size (~400 bp) in DNA gel electrophoresis for both primer pools. PCR products were purified with AMPure XP magnetic beads (Beckman Coulter) and quantified using Qubit 4.0 fluorometer (ThermoFisher). DNA libraries were generated using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs), reducing all reagents volumes to 25% from the manufacturer's recommended protocol to increase throughput. The resulting products were screened for size and quality using the Bioanalyzer 2100 instrument (Agilent Technologies) and quantified with Qubit 4 fluorometer (ThermoFisher). Qualifying libraries were pooled and run in the MiSeq sequencer instrument (Illumina) using the MiSeq Reagent Kit v3 in 600-cycle program.
The resulting sequence reads were screened for quality, trimmed, and assembled into complete consensus SARS-CoV-2 genomes using the Genome Detective Virus Tool v1.13632 (https://www.genomedetective.com) and assembly confirmed with iVar33. The Pangolin COVID-19 Lineage Assigner tool was used for lineage assignment34 (https://pangolin.cog-uk.io). A total of 753 samples were sequenced with more than 95% genome coverage at a minimum of 10x sequence depth. All sequence data obtained for this study was submitted to GISAID, accession numbers available in Supplementary Data 1.
Phylogenetic analysis
Our Puerto Rico SARS-CoV-2 genomes dataset was analyzed against a diverse panel of genomes from across the world which provide regional phylogenetic context. Initially, we downloaded the Genomic Epidemiology metadata package for all entries from GISAID on August 18th, 2021 to screen genomes for subsampling. However, due to the large number of genomes available in GISAID, we downloaded and combined the following pre-sampled datasets for regional studies: NextRegion-North America, NextRegion-South America, and NextRegion-Global. We then used the standard ncov augur/auspice multiple input workflow available in the Nextstrain platform35 (https://github.com/nextstrain/ncov) to subsample contextual genomes and phylogenetic inference with time-stamped trees. The custom subsampling scheme program selected 2611 contextual genomes from the United States, North America, the Caribbean, Central America, South America, Africa, Europe, Asia, and Oceania, with higher proportions from The Americas and selected based on collection dates and genetic proximity to our Puerto Rico dataset. The combined dataset of 3364 genomes was aligned using MAFFT36 and a global maximum likelihood (ML) phylogenetic inference was reconstructed with IQ-TREE37. The ncov workflow then transferred the ML tree to TreeTime38 for time calibration and ancestral state reconstruction of the tree topology at constate rate of 8 × 10−4 nucleotide substitutions per site per year. The resulting global ML tree was visualized with Nextstrain auspice35 and annotated with iTol for region of origin and emerging variants39. Subsampling from the Genomic Epidemiology metadata package retrieved in August and from the combined NextRegions produced phylogenetic inference trees with similar topologies. A list of all the sequences used in this study, including sequence labels and authors can be found in the “Data availability” section.
Selected lineages of interest were studied further by reconstruction of phylogenetic focus trees. For the B.1.588 lineage-focused tree, we selected all B.1.588 genomes published in GISAID by October 31st, 2021. Contextual B.1 lineage genomes were selected based on phylogenetic clustering near the base of the B.1.588 clade in the global tree and by temporal proximity to the date range of B.1.588 circulation between June 2020 and January 2021. Maximum likelihood phylogenetic trees were reconstructed with the resulting dataset of 239 genomes under the GTR + G + I nucleotide substitution model and 1000 bootstrap replicates using IQ-TREE v1.6.1237. The resulting tree topology and node support were compared to Bayesian maximum clade credibility (MCC) tree reconstruction using BEAST v1.10.454. The sampling for this study was also limited due to the ability of our partnership to procure samples from every municipality of the island, especially during the first year of the local epidemic. The availability of case metadata, such as travel history, was also limited, which would have facilitated an in-depth analysis on the impact of importations on the island. Future national genomic surveillance programs could benefit from improved systematic sampling engaging with clinical laboratories to ensure timely reporting of results to the local public health authorities, proper sample storage, and transfer to sequencing laboratories. Regarding phylogenetic analyses, the slow mutation rate and the low genetic diversity of the virus frequently impair the resolution of internal nodes with statistical support affecting the interpretation of phylogenetic histories and geographic origins. These analyses could also be affected by selecting context genomes from the unprecedented abundance of genomic data published in GISAID.
This study provides an overview of the COVID-19 epidemic in Puerto Rico during March 2020–November 2021 from the genomic epidemiology perspective. The documentation of an autochthonous lineage and dynamics of virus movement between the United States and Puerto Rico is important to inform prevention and surveillance efforts in both regions. Our phylogenetic study offers the genomic framework to understand the genomic changes occurring through time in the Puerto Rican viral population and elucidate the mutational landscape within this region. Furthermore, our ongoing genomic surveillance initiative will facilitate the study of SARS-CoV-2 intra-island phylodynamics and compare pre- and post-vaccination populations. Finally, this report highlights the importance of government and academic partnerships to respond to public health threats and the potential of systematic genomic surveillance to improve disease prevention and control.
Data availability
All genome sequences and associated metadata in this dataset are published in GISAID’s EpiCoV database. To view the contributors of each individual sequence with details such as accession number, virus name, collection date, originating lab and submitting lab, and the list of authors, please visit https://doi.org/10.55876/gis8.220722zw55 for contextual genomes and Supplementary Data 1 for the list of genomes generated by this study.
References
World Health Organization (WHO). Novel Coronavirus (2019-nCoV). Situation Report-1. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2021).
World Health Organization (WHO). Novel Coronavirus (2019-nCoV). Situation Report-51. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2021).
World Health Organization (WHO). Weekly epidemiological update on COVID-19. Edition 66. 16 November 2021. WHO. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-16-november-2021 (2021).
World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (2021).
Fauver, J. R. et al. Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. Cell 181, 990–996.e995 (2020).
Gharpure, R. et al. Multistate outbreak of SARS-CoV-2 infections, including vaccine breakthrough infections, associated with large public gatherings, United States. Emerg. Infect. Dis. 28, 35–43 (2021).
Worobey, M. et al. The emergence of SARS-CoV-2 in Europe and North America. Science 370, 564–570 (2020).
Perkins, T. A. et al. Estimating unobserved SARS-CoV-2 infections in the United States. Proc. Natl Acad. Sci. USA 117, 22597–22602 (2020).
Zeller, M. et al. Emergence of an early SARS-CoV-2 epidemic in the United States. Cell 184, 4939–4952.e4915 (2021).
Minskaia, E. et al. Discovery of an RNA virus 3’->5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl Acad. Sci. USA 103, 5108–5113 (2006).
Duchene, S. et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 6, veaa061 (2020).
Benvenuto, D. et al. The 2019-new coronavirus epidemic: evidence for virus evolution. J. Med. Virol. 92, 455–459 (2020).
Giovanetti, M. et al. Evolution patterns of SARS-CoV-2: snapshot on its genome variants. Biochem. Biophys. Res. Commun. 538, 88–91 (2021).
Roy, U. Comparative structural analyses of selected spike protein-RBD mutations in SARS-CoV-2 lineages. Immunol. Res. 70, 143–151 (2022).
Bhattacharya, M., Chatterjee, S., Sharma, A. R., Agoramoorthy, G. & Chakraborty, C. D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. Appl. Microbiol. Biotechnol. 105, 9035–9045 (2021).
Kepler, L., Hamins-Puertolas, M. & Rasmussen, D. A. Decomposing the sources of SARS-CoV-2 fitness variation in the United States. Virus Evol. 7, veab073 (2021).
Korber, B. et al. Tracking Changes in SARS-CoV-2 Spike: evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182, 812–827 e819 (2020).
Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266–269 (2021).
Washington, N. L. et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184, 2587–2594.e2587 (2021).
Alpert, T. et al. Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. Cell 184, 2595–2604.e2513 (2021).
Truelove, S. et al. Projected resurgence of COVID-19 in the United States in July-December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination. Elife, 11, e73584 (2022).
Centers for Disease Control and Prevention (CDC). COVID-19: SARS-CoV-2 variant classifications and definitions. Atlanta, GA: US Department of Health and Human Services. 2021. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html) (2021).
England Public Health. SARS-CoV-2 variants of concern and variants under investigation in England—technical briefing 17. London, United Kingdom: Public Health England; 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdf (2021).
The COVID-19 Genomics UK (COG-UK) consortiumcontact@cogconsortium.uk. An integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe 1, e99–e100 (2020).
Brito, A. F. et al. Global disparities in SARS-CoV-2 genomic surveillance. Preprint at medRxiv https://doi.org/10.1101/2021.08.21.21262393 (2021).
Puerto Rico Department of Health. COVID-19 in Puerto Rico Dashboard. https://covid19datos.salud.gov.pr/ (2021).
Government of Puerto Rico. Department of State. Executive Orders-15 March 2020. https://www.estado.pr.gov/en/executive-orders/ (2020).
Moreland, A. et al. Timing of state and territorial COVID-19 stay-at-home orders and changes in population Movement—United States, March 1-May 31, 2020. Morb. Mortal Wkly. Rep. 69, 1198–1203 (2020).
Santiago, G. A. et al. Tracing the origin, spread, and molecular evolution of Zika Virus in Puerto Rico, 2016-2017. Emerg. Infect. Dis. 27, 2971–2973 (2021).
Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407 (2020).
O’Toole, A. et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 7, veab064 (2021).
Vilsker, M. et al. Genome detective: an automated system for virus identification from high-throughput sequencing data. Bioinformatics 35, 871–873 (2019).
Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 20, 8 (2019).
Russell, A. et al. Spatiotemporal analyses of 2 co-circulating SARS-CoV-2 variants, New York state, USA. Emerg. Infect. Dis. 28, 650–659 (2022).
Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121–4123 (2018).
Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30, 3059–3066 (2002).
Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).
Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: maximum-likelihood phylodynamic analysis. Virus Evol 4, vex042 (2018).
Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics 23, 127–128 (2007).
Drummond, A. J., Suchard, M. A., **e, D. & Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29, 1969–1973 (2012).
Hodcroft, E. SARS-CoV-2 Variants webstite: https://covariants.org/per-country.
Leite, J. A. et al. Implementation of a COVID-19 genomic surveillance regional network for Latin America and Caribbean region. PLoS ONE 17, e0252526 (2022).
Turakhia, Y. et al. Stability of SARS-CoV-2 phylogenies. PLoS Genet. 16, e1009175 (2020).
Munis, A. M., Andersson, M., Mobbs, A., Hyde, S. C. & Gill, D. R. Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown. Sci. Rep. 11, 21484 (2021).
Happi, A. N., Ugwu, C. A. & Happi, C. T. Tracking the emergence of new SARS-CoV-2 variants in South Africa. Nat. Med. 27, 372–373 (2021).
Molina-Mora, J. A. et al. SARS-CoV-2 genomic surveillance in Costa Rica: Evidence of a divergent population and an increased detection of a spike T1117I mutation. Infect. Genet. Evol. 92, 104872 (2021).
Resende, P. C. et al. Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B.1.1.33 during the early pandemic phase in Brazil. Front. Microbiol. 11, 615280 (2020).
Tordoff, D. M. et al. Phylogenetic estimates of SARS-CoV-2 introductions into Washington state. Lancet Reg. Health Am. 1, 100018 (2021).
Ferreira, I. et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J. Infect. Dis. 224, 989–994 (2021).
Rodriguez-Grande, C. et al. SARS-CoV-2 B.1.1.7 decline is not driven by the introduction of a more successful variant. Microbiol. Spectr. 9, e0112821 (2021).
Centers for Disease Control and Prevention (CDC). COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services. 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions (2022).
Charre, C. et al. Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation. Virus Evol. 6, veaa075 (2020).
Mavian, C. et al. Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. Proc. Natl Acad. Sci. USA 117, 12522–12523 (2020).
Kubik, S. et al. Recommendations for accurate genoty** of SARS-CoV-2 using amplicon-based sequencing of clinical samples. Clin. Microbiol. Infect. 27, 1036 e1031–1036.e1038 (2021).
Santiago, G. A. et al. GISAID EPI_SET_20220722zw metadata and list of contextual genome sequences used in this study including sequence author acknowledgements. https://doi.org/10.55876/gis8.220722zwhttps://epicov.org/epi3/epi_set/EPI_SET_20220722zw?main=true.
Acknowledgements
We thank our partners from the Puerto Rico Department of Health, especially the staff from the Institute of Public Health Laboratories and the Biological and Chemical Emergencies Laboratory, for their contribution to the genomic surveillance framework and sample procurement. We also thank Dr. Anderson Brito and Chaney Kalinich, former members of the Dr. Nathan Grubaugh laboratory at the Yale School of Public Health, New Haven, CT, for providing invaluable technical assistance with data analysis. We acknowledge all healthcare workers and authors submitting data to GISAID, “Data availability” section, https://doi.org/10.55876/gis8.220722zw. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Institute of Health. This project was partially funded by the Centers for Disease Control and Prevention’s Advanced Molecular Detection Program and the COVID-19 Laboratory Task Force, the Puerto Rico Science, Technology and Research Trust (VRA), CDC U54MD007579 (VRA), and CDC U01CK000580 (VRA). Additional funding for this study was provided by the National Institute of General Medical Sciences of the National Institute of Health under award number U54GM133807 (NoA: 5U54GM133807-02) to Dr. Riccardo Papa. This project was also supported by UPR COVID-19 emergency funds #2020-2488 to Dr. Riccardo Papa.
Author information
Authors and Affiliations
Contributions
G.A.S. and J.L.M.J. conceived and designed the study with contributions from R.P., S.M.V.B., and E.O. B.F., G.L.G., K.N.C., L.C.H., and S.M.V.B. contributed to genomic sequencing, data analysis, and interpretation of results. G.A.S. drafted the manuscript with contributions from B.F., G.L.G., K.N.C., L.C.H., S.M.V.B., and J.L.M.J. H.R.V., V.R.A., L.E.A., M.M., L.H., I.C., E.O., G.P.B., R.P., and J.L.M.J. contributed to the revision and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Communications Medicine thanks Robert Paulino-Ramirez and the other anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Santiago, G.A., Flores, B., González, G.L. et al. Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants. Commun Med 2, 100 (2022). https://doi.org/10.1038/s43856-022-00168-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s43856-022-00168-7
- Springer Nature Limited